Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (191-200 of 437) with videos related to

Pageof 44
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 2, 2008
Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancerFilippo de Marinis, Jose Rodrigues Pereira, Frank Fossella, et al.
Translational Lung Cancer Research|January 20, 2025
A non-interventional biomarker study in patients with adenocarcinoma of the lung treated with nintedanib plus docetaxel following progression on chemotherapy and/or immunotherapy: LUME-BioNISMartin Reck, Konstantinos Syrigos, Skaidrius Miliauskas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 1, 2020
Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 AssayHans Juergen Grote, Zheng Feng, Michael Schlichting, et al.
Clinical Lung Cancer|February 27, 2026
TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung CancerLuis G Paz-Ares, Kenneth John O'Byrne, Melissa L Johnson, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2019
Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group surveyAntonin Levy, Lizza E L Hendriks, Cécile Le Péchoux, et al.
Clinical Lung Cancer|February 25, 2014
Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancerJoachim von Pawel, Jimmie H Harvey, David R Spigel, et al.
Respiratory Medicine|October 13, 2009
Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in GermanyMartin Reck, Rolf A Stahel, Joachim von Pawel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin statusMartin J Edelman, Claus-Peter Schneider, Chun-Ming Tsai, et al.
Scientific Reports|May 6, 2021
Identification of molecular signatures associated with early relapse after complete resection of lung adenocarcinomasHelen Pasternack, Christiane Kuempers, Mario Deng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesotheliomaRaffit Hassan, Hedy L Kindler, Thierry Jahan, et al.
Pageof 44

Showing results (191-200 of 437) with videos related to

Sort By:
Pageof 44
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 2, 2008
Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancerFilippo de Marinis, Jose Rodrigues Pereira, Frank Fossella, et al.
Translational Lung Cancer Research|January 20, 2025
A non-interventional biomarker study in patients with adenocarcinoma of the lung treated with nintedanib plus docetaxel following progression on chemotherapy and/or immunotherapy: LUME-BioNISMartin Reck, Konstantinos Syrigos, Skaidrius Miliauskas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 1, 2020
Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 AssayHans Juergen Grote, Zheng Feng, Michael Schlichting, et al.
Clinical Lung Cancer|February 27, 2026
TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung CancerLuis G Paz-Ares, Kenneth John O'Byrne, Melissa L Johnson, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2019
Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group surveyAntonin Levy, Lizza E L Hendriks, Cécile Le Péchoux, et al.
Clinical Lung Cancer|February 25, 2014
Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancerJoachim von Pawel, Jimmie H Harvey, David R Spigel, et al.
Respiratory Medicine|October 13, 2009
Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in GermanyMartin Reck, Rolf A Stahel, Joachim von Pawel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin statusMartin J Edelman, Claus-Peter Schneider, Chun-Ming Tsai, et al.
Scientific Reports|May 6, 2021
Identification of molecular signatures associated with early relapse after complete resection of lung adenocarcinomasHelen Pasternack, Christiane Kuempers, Mario Deng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesotheliomaRaffit Hassan, Hedy L Kindler, Thierry Jahan, et al.
Pageof 44